JP2016516076A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516076A5
JP2016516076A5 JP2016503654A JP2016503654A JP2016516076A5 JP 2016516076 A5 JP2016516076 A5 JP 2016516076A5 JP 2016503654 A JP2016503654 A JP 2016503654A JP 2016503654 A JP2016503654 A JP 2016503654A JP 2016516076 A5 JP2016516076 A5 JP 2016516076A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
insulin
chain
long
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516076A (ja
JP6755175B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055533 external-priority patent/WO2014147141A1/en
Publication of JP2016516076A publication Critical patent/JP2016516076A/ja
Publication of JP2016516076A5 publication Critical patent/JP2016516076A5/ja
Application granted granted Critical
Publication of JP6755175B2 publication Critical patent/JP6755175B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503654A 2013-03-20 2014-03-19 インスリン投薬レジメン Active JP6755175B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13160194 2013-03-20
EP13160194.0 2013-03-20
US201361804363P 2013-03-22 2013-03-22
US61/804,363 2013-03-22
PCT/EP2014/055533 WO2014147141A1 (en) 2013-03-20 2014-03-19 Insulin dosing regimen

Publications (3)

Publication Number Publication Date
JP2016516076A JP2016516076A (ja) 2016-06-02
JP2016516076A5 true JP2016516076A5 (OSRAM) 2017-04-27
JP6755175B2 JP6755175B2 (ja) 2020-09-16

Family

ID=47900938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503654A Active JP6755175B2 (ja) 2013-03-20 2014-03-19 インスリン投薬レジメン

Country Status (5)

Country Link
US (4) US20160296602A1 (OSRAM)
EP (1) EP2976096B1 (OSRAM)
JP (1) JP6755175B2 (OSRAM)
CN (1) CN105188736A (OSRAM)
WO (1) WO2014147141A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー/エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
EP3544682A1 (en) * 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
JP7193455B2 (ja) 2016-11-28 2022-12-20 ノヴォ ノルディスク アー/エス 心血管状態におけるインスリンデグルデク
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
CN110248964B (zh) 2017-02-01 2024-08-27 诺和诺德股份有限公司 促凝血抗体
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
EP3815106B1 (en) * 2018-06-26 2024-12-25 Novo Nordisk A/S System providing dose recommendations for basal insulin titration
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
BR112021011156A2 (pt) 2018-12-11 2021-10-26 Sanofi Conjugados de insulina
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012347A2 (en) * 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
EP2264066A3 (en) * 2003-08-05 2011-07-27 Novo Nordisk A/S Novel insulin derivatives
PT1969004E (pt) * 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
CN101454019A (zh) * 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
WO2009022006A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
ES2607003T3 (es) * 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
MX2012012943A (es) * 2010-05-10 2012-11-29 Novo Nordisk As Proceso para preparacion de complejos de insulina-cinc.
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
SI2632478T1 (sl) * 2010-10-27 2019-11-29 Novo Nordisk As Zdravljenje sladkorne bolezni z uporabo inzulinskih injekcij, ki se dajejo v različnih injicirnih intervalih
WO2012104339A1 (en) * 2011-02-01 2012-08-09 Novo Nordisk A/S Purification of insulin
EP4070801A1 (en) * 2011-03-01 2022-10-12 Nutrition 21, LLC Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
EP2844274B1 (en) * 2012-05-01 2019-03-20 Novo Nordisk A/S Pharmaceutical composition
US10137172B2 (en) * 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime

Similar Documents

Publication Publication Date Title
JP2016516076A5 (OSRAM)
DK1965823T3 (en) Methods of administering hypoglycemics
RU2011117645A (ru) Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
AU2016202917B2 (en) Treating diabetes melitus using insulin injections administered with varying injection intervals
Lee et al. Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
JP2007523881A5 (OSRAM)
RU2012123739A (ru) Фармацевтическая композиция, содержащая агонист гпп-1 и метионин
Choe et al. Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists
RU2014126244A (ru) Лекарственные средства, содержащие аминокислотные последовательности инсулина
JP2014501762A5 (OSRAM)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
AR071990A1 (es) Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto
JP2009533460A (ja) hGLP−1、エクセンジン−4およびその類似体の医薬組成物
JP2011241213A5 (OSRAM)
JP2011001381A (ja) Glp−1医薬組成物
EP2185178A2 (en) Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
JP2014520798A (ja) ポリエチレングリコールまたはその誘導体でpeg化されたエキセンジン−4類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物
JP2010031018A5 (OSRAM)
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
JP2013526501A5 (OSRAM)
Brandt et al. Are peptide conjugates the golden therapy against obesity?
JP2015517458A5 (OSRAM)
RU2014147674A (ru) Фармацевтическая композиция
CN110013542B (zh) 一种预防/治疗突触核蛋白病的药物及多肽类似物
Woo A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus